Get the Stockscreener App
18.13
6.27%
1.07
After Hours:
18.13
Viridian Therapeutics Inc stock is traded at $18.13, with a volume of 1.13M.
It is up +6.27% in the last 24 hours and down -12.92% over the past month.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
See More
Previous Close:
$17.06
Open:
$17.31
24h Volume:
1.13M
Relative Volume:
0.88
Market Cap:
$1.44B
Revenue:
$288.00K
Net Income/Loss:
$-228.06M
P/E Ratio:
-4.2659
EPS:
-4.25
Net Cash Flow:
$-168.82M
1W Performance:
-0.38%
1M Performance:
-12.92%
6M Performance:
+18.96%
1Y Performance:
-18.74%
1-Day Range:
$17.13
$18.43
1-Week Range:
$16.60
$18.43
52-Week Range:
$11.40
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics Inc
Sector
Industry
Phone
617.272.4600
Address
221 CRESCENT STREET, WALTHAM
Compare VRDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
18.13 | 1.44B | 288.00K | -228.06M | -168.82M | -4.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Initiated | TD Cowen | Buy |
| Sep-11-24 | Reiterated | Needham | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| May-09-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-09-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-14-23 | Initiated | BTIG Research | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-17-23 | Initiated | Wells Fargo | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Dec-19-22 | Initiated | Cowen | Outperform |
| Dec-19-22 | Initiated | Needham | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Dec-01-22 | Initiated | H.C. Wainwright | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Nov-18-21 | Initiated | SVB Leerink | Outperform |
| Oct-12-21 | Initiated | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Viridian Therapeutics Inc Stock (VRDN) Latest News
Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen - MSN
Viridian Therapeutics Stock Hits 3-Week High, Retail Buzz Builds On Chronic Thyroid Eye Disease Trial Data - MSN
Viridian Therapeutics (NASDAQ:VRDN) Trading Up 6.3%What's Next? - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Sees Significant Growth in Short Interest - MarketBeat
JPMorgan Chase & Co. Purchases 274,641 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
JPMorgan Chase & Co. Raises Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Earns “Buy” Rating from Needham & Company LLC - Defense World
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - BioSpace
Viridian Therapeutics, Inc. Promotes Seth Harmon to the Role of Chief Financial Officer - Marketscreener.com
(VRDN) Investment Analysis - Stock Traders Daily
Acelyrin To Take Tepezza Competitor Into Phase III In TED - Citeline News & Insights
Viridian Therapeutics (NASDAQ:VRDN) Shares Up 5.8%Here's Why - MarketBeat
Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts - Benzinga
Viridian Therapeutics (NASDAQ:VRDN) Earns Buy Rating from Needham & Company LLC - MarketBeat
Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $35.70 - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Principal Financial Group Inc. Acquires 162,665 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Principal Financial Group Inc. Boosts Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Geode Capital Management LLC Grows Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Geode Capital Management LLC Has $33.98 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$19.3 Based On Its Intrinsic Value? - Yahoo Finance
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Barclays PLC - Defense World
Barclays PLC Boosts Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Trading Down 3.4%What's Next? - MarketBeat
Contrasting Viridian Therapeutics (NASDAQ:VRDN) and Zicix (OTCMKTS:ZICX) - Defense World
Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$18.7 Based On Its Intrinsic Value? - Simply Wall St
Wells Fargo Downgrades Viridian Therapeutics (VRDN) - MSN
Viridian Therapeutics (NASDAQ:VRDN) Shares Gap DownTime to Sell? - MarketBeat
Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade) - Seeking Alpha
Wells Fargo & Company Reiterates "Equal Weight" Rating for Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by State Street Corp - Defense World
State Street Corp Has $54.14 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation - Seeking Alpha
Viridian stock soars 25% on Phase 3 data for veligrotug - MSN
Viridian Therapeutics sees stock soar after Phase III TED success - MSN
When (VRDN) Moves Investors should Listen - Stock Traders Daily
Viridian Therapeutics (NASDAQ:VRDN) Trading Down 5.7%Here's What Happened - MarketBeat
Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views - Benzinga
Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade) (NASDAQ:VRDN) - Seeking Alpha
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $47.00 at Royal Bank of Canada - MarketBeat
Viridian veers upwards on Phase III success - The Pharma Letter
Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints - Yahoo Finance
Viridian Therapeutics' SWOT analysis: thyroid eye disease stock poised for growth - Investing.com India
Lord Abbett & CO. LLC Takes $8.92 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Wellington Management Group LLP Decreases Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Given Buy Rating at HC Wainwright - Defense World
Viridian taking on Amgen in TED market - BioCentury
Viridian Continues Building Case For Veligrotug In TED - News & Insights
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday - Benzinga
Viridian Therapeutics (NASDAQ:VRDN) Shares Gap UpHere's Why - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Receives Buy Rating from HC Wainwright - MarketBeat
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):